Related references
Note: Only part of the references are listed.Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
Jeffrey Yang et al.
MEDICINAL RESEARCH REVIEWS (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Hsin-Pei Shih et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
PD-L1 inhibitors in the pipeline: Promise and progress
Vito Vanella et al.
ONCOIMMUNOLOGY (2018)
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results
Christoph Schwarz et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Belatacept and Autoimmune Adverse Events
Simon Ville et al.
TRANSPLANTATION (2018)
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
Apoorvi Chaudhri et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study
Aravindhan Ganesan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Small-Molecule Targets in Tumor Immunotherapy
Hui-Fang Zhu et al.
NATURAL PRODUCTS AND BIOPROSPECTING (2018)
UniProt: the universal protein knowledgebase
Alex Bateman et al.
NUCLEIC ACIDS RESEARCH (2017)
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells
Xiong Ni et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
Katarzyna Guzik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Coinhibitory Receptor expression and immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic viral infections and Cancer
Isobel S. Okoye et al.
FRONTIERS IN IMMUNOLOGY (2017)
Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets
Hwei-Fang Tsai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis
Marco Scarpa et al.
BMC CANCER (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Qianxia Zhang et al.
IMMUNITY (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
T cells in the control of organ-specific autoimmunity
Jeffrey A. Bluestone et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Anna Sledzinska et al.
MOLECULAR ONCOLOGY (2015)
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Michael J. Waring et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram et al.
CLINICAL CANCER RESEARCH (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
D. Gardner et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
Hubert G. Nuesslein et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function
Tanya Girard et al.
IMMUNOLOGY LETTERS (2014)
Targeting co-stimulatory pathways: transplantation and autoimmunity
Mandy L. Ford et al.
NATURE REVIEWS NEPHROLOGY (2014)
T Cell Receptor Signaling Can Directly Enhance the Avidity of CD28 Ligand Binding
Mariano Sanchez-Lockhart et al.
PLOS ONE (2014)
The role of B7 family molecules in hematologic malignancy
Paul Greaves et al.
BLOOD (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Leslie A. Fecher et al.
ONCOLOGIST (2013)
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Ruihua Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
B7-H5 costimulates human T cells via CD28H
Yuwen Zhu et al.
NATURE COMMUNICATIONS (2013)
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Ahmad Tarhini
SCIENTIFICA (2013)
Summary of the US FDA Approval of Belatacept
P. Archdeacon et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
M. S. Czuczman et al.
ANNALS OF ONCOLOGY (2012)
CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma
Naveen Dakappagari et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2012)
Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC
Martin F. Flajnik et al.
IMMUNOGENETICS (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Joanne Bowes et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
Lukas Baitsch et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
B7-H2 Is a Costimulatory Ligand for CD28 in Human
Sheng Yao et al.
IMMUNITY (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2011)
Protective HIV-specific CD8+ T cells evade Treg cell suppression
Shokrollah Elahi et al.
NATURE MEDICINE (2011)
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
Virginia A. Pedicord et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A more selective costimulatory blockade of the CD28-B7 pathway
Nicolas Poirier et al.
TRANSPLANT INTERNATIONAL (2011)
Inflammatory cytokines as a third signal for T cell activation
Julie M. Curtsinger et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Galiximab: a review
Seema Bhat et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
The Role of CD80/CD86 in Generation and Maintenance of Functional Virus-Specific CD8+ T Cells in Mice Infected with Lymphocytic Choriomeningitis Virus
Mirjana Grujic et al.
JOURNAL OF IMMUNOLOGY (2010)
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Flavio Vincenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Margaret K. Callahan et al.
SEMINARS IN ONCOLOGY (2010)
Strategies and challenges for the next generation of therapeutic antibodies
Alain Beck et al.
NATURE REVIEWS IMMUNOLOGY (2010)
The role of innate immune responses in autoimmune disease development
Hanspeter Waldner
AUTOIMMUNITY REVIEWS (2009)
Abatacept, a Novel CD80/86-CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis
Riku Korhonen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Kent S. Boles et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention
Daniel E. Kaufmann et al.
JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The B7 family and cancer therapy: Costimulation and coinhibition
Xingxing Zang et al.
CLINICAL CANCER RESEARCH (2007)
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
J. P. Leonard et al.
ANNALS OF ONCOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Discovery of selective small-molecule CD80 inhibitors
Kristina Uvebrant et al.
JOURNAL OF BIOMOLECULAR SCREENING (2007)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma
I Tirapu et al.
CANCER RESEARCH (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Different cell surface oligomeric states of B7-1 and B7-2: Implications for signaling
S Bhatia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Costimulation blockade with belatacept in renal transplantation
F Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The B7/CD28 costimulatory family in autoimmunity
ME Keir et al.
IMMUNOLOGICAL REVIEWS (2005)
Crystal structure of a soluble CD28-Fab complex
EJ Evans et al.
NATURE IMMUNOLOGY (2005)
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator
JR Sedy et al.
NATURE IMMUNOLOGY (2005)
Role of B7 costimulatory molecules in immune responses and T-helper cell differentiation in response to recombinant HagB from Porphyromonas gingivalis
P Zhang et al.
INFECTION AND IMMUNITY (2004)
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease
S Paust et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
High-affinity small molecule inhibitors of T cell costimulation: Compounds for immunotherapy
P Huxley et al.
CHEMISTRY & BIOLOGY (2004)
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions
PA Taylor et al.
JOURNAL OF IMMUNOLOGY (2004)
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses
WK Suh et al.
NATURE IMMUNOLOGY (2003)
Structure-activity studies of a series of dipyrazolo[3,4-b:3′,4′-d]pyridin-3-ones binding to the immune regulatory protein B7.1
NJ Green et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N Watanabe et al.
NATURE IMMUNOLOGY (2003)
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity
GL Sica et al.
IMMUNITY (2003)
B7S1, a novel B7 family member that negatively regulates T cell activation
DVR Prasad et al.
IMMUNITY (2003)
Costimulation of T cells by OX40, 4-1BB, and CD27
M Croft
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling
XW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Condensed aromatic peptide family of microbial Metabolites, inhibitors of CD28-CD80 interactions
VR Hegde et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Acquisition of CD80 by human T cells at early stages of activation: Functional involvement of CD80 acquisition in T cell to T cell interaction
Z Tatari-Calderone et al.
JOURNAL OF IMMUNOLOGY (2002)
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Antibodies to B7.1 define the GFCC′C face of the N-terminal domain as critical for co-stimulatory interactions
SY Wang et al.
IMMUNOLOGY LETTERS (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma
S Suvas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
Small molecule Ligands define a binding site on the immune regulatory protein B7.1
DV Erbe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory
M Suresh et al.
JOURNAL OF IMMUNOLOGY (2001)
Differential role of CD80 and CD86 molecules in the induction and the effector phases of allergic rhinitis in mice
M Okano et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
An important role of CDK inhibitor p18INK4c in modulating antigen receptor-mediated T cell proliferation
GI Kovalev et al.
JOURNAL OF IMMUNOLOGY (2001)
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
JL Cannons et al.
JOURNAL OF IMMUNOLOGY (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
JCD Schwartz et al.
NATURE (2001)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)
Acquisition of CD80 (B7-1) by T cells
H Sabzevari et al.
JOURNAL OF IMMUNOLOGY (2001)
CTLA-4 up-regulation plays a role in tolerance mediated by CD45
S Fecteau et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS
SK Yoshinaga et al.
INTERNATIONAL IMMUNOLOGY (2000)
Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
JR Abrams et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice
K Kinoshita et al.
JOURNAL OF IMMUNOLOGY (2000)
Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population
DE Anderson et al.
NATURE MEDICINE (2000)
Structure and dimerization of a soluble form of B7-1
S Ikemizu et al.
IMMUNITY (2000)
Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection
JM Lumsden et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
